Companies To Watch: Corner Therapeutics

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Corner Therapeutics is in early development of dendritic cell hyperactivators (hDC), seeking to fill in a large gap in cancer immunotherapy: lack of sufficient memory T cells to attack and defend against tumors over patients’ lifetimes. Corner’s hDC therapy would require small biopsies to capture cancer antigens from each patient for the hyperactivated dendritic T cells to target. The treatment would achieve the long sought-after goal of a cancer vaccine, inducing durable immunity, and future applications could possibly extend to infectious diseases as well.